Sinovac - A leading vaccine company in China

Our Products: Hepatitis

A R&D Oriented company

An Integrated Vaccine Company

Our Products: Influenza

A Nasdaq Listed Company

We are:
1st company to develop inactivated hepatitis A vaccine in China
1st company to develop combined hepatitis A and B vaccine in China
1st company to complete phase I clinical trial on SARS vaccine worldwide
1st company to develop H5N1 vaccine in China
1st company to develop and get license of H1N1 vaccine worldwide
1st and only Chinese vaccine company listed in Nasdaq
Our Mission

Supply Vaccines To Eliminate Human Diseases

- Provide Chinese Population with International Quality Vaccines
- Provide Vaccines Made in China to Worldwide

Our Products: Hepatitis

Our Products: Influenza

Our Products:
Manufacturing Facilities

Manufacturing Plants

**Headquarter - Beijing**
- Healive production plant
  - Capacity: 10 million
- Filling & Packaging Plant
  - Capacity: 20 million
- Anflu Production plant
  - Capacity: 8 million

**Dalian**
- Vero Cell Cultured Vaccine and Live Attenuated Vaccine
  - Capacity: 6-15 million
  - Building Area: 95,000 square meters

**Tangshan**
- Yi’an Animal Vaccine
  - Capacity: 5-20 million
  - Building Area: 13,500 square meters

**Changping District, Beijing**
- Novel Vaccine Production Base
  - Capacity of Filling and Packaging: 100 million
  - Capacity of EV71: 10-20 million
  - Building Area: 29,000 square meters
Hand Foot Mouth Disease Epidemic

New Zealand, Hand Foot Mouth Disease was reported and defined

Bulgaria, 705 cases, 44 deaths

US, EV71 was isolated

Malaysia, 2628 cases, 30 deaths

Taiwan, 129106 cases, 78 deaths

Mainland of China, Korea, Viet Nam, etc. millions cases reported and thousands dead

**EV71 Epidemic in China**

**Serious HFMD epidemic in China;**
**EV71 inducing main serious and fatal cases;**
**Vaccine against EV71 is the answer.**

*《Hand, foot, and mouth disease in China, 2008–12: An epidemiological study》*
## Development Milestones

<table>
<thead>
<tr>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-clinical study</td>
<td>IND Application</td>
<td>Clinical study</td>
<td>Industrialization</td>
<td>NDA Application</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **2008**: Pre-clinical study
- **2009**: IND Application
- **2010**: Clinical study
- **2011**: IND Application
- **2012**: Clinical study
- **2013**: NDA Application
- **2014**: Industrialization

- **2010.12**: Clinical approval
- **2013.5**: NDA application
Characters of Sinovac EV71 Vaccine

- Vero Cell, cell factory cultivation technology;
- H07 strain, C4 subgenotype, isolated by China CDC;
- Inactivation with formaldehyde
- Al(OH)3 as adjuvant
- 100 u/200u/400 u, 2 doses/3 doses regimen
EV71 Vaccine Clinical Trials

Phase I
- Objective: Safety, Immunogenicity
- Subjects: Babies, children, and Adult
- Dose: 100U, 200U, 400U
- Subjects: 168

Phase II
- Objective: Immunogenicity, safety
- Subjects: 6-35 months babies
- Dose: 100U, 200U, 400U
- Subjects: 540

Phase III
- Objective: Protective effective
- Subjects: 6-35 months babies
- Dose: 400U
- Subjects: 10077

Phase III
- Objective: consistency
- Subjective: 6 months-5 years children
- Dose: 400U
- Subjects: 1400

All trials following GCP
No significant difference between vaccine group and placebo group

**EV71 Vaccine - Efficacy**

**Protection rate for EV71 infection:** 94.3%

**Protection for hospitalized cases and serious cases:** 100.0%

56 days after vaccination, Neutralizing antibody positive rate 98.79%, GMT 165.79, 8 months and 14 months after vaccination, high level of antibody.

Good immunogenicity and immune persistence.
# Industrialization

## Production
19000 m²

<table>
<thead>
<tr>
<th>Floor</th>
<th>Area</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4F</td>
<td></td>
<td>Ready for use</td>
</tr>
<tr>
<td>3F</td>
<td></td>
<td>QC Labs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EV71 Bulk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20 million does/year</td>
</tr>
<tr>
<td>2F</td>
<td></td>
<td>Formulation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Filling &amp; Packaging</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 million doses/year</td>
</tr>
<tr>
<td>1F</td>
<td></td>
<td>Cold Room</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.8 million vials</td>
</tr>
</tbody>
</table>

## Others
4000 m²

<table>
<thead>
<tr>
<th>Floor</th>
<th>Area</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2F</td>
<td></td>
<td>Animal Lab</td>
</tr>
<tr>
<td>1F</td>
<td></td>
<td>Biobank</td>
</tr>
</tbody>
</table>

## Office
9000 m²

| Total area: 29,021 m² |
| Built-up area: 32,322 m² |
Supply vaccines to eliminate human diseases

谢谢！

提供国际水平的疫苗给中国儿童

提供给世界儿童使用中国制造的疫苗